NCT03340064View on ClinicalTrials.gov

A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

June 1, 2021

Study Completion Date

July 28, 2023

Conditions

Partial Seizures

Interventions

DRUG

Levetiracetam

levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)

Trial Locations (21)

Unknown

Ep0100 15, Fukuoka

EP0100 3, Hamamatsu

EP0100 6, Izumi

Ep0100 20, Kobe

EP0100 2, Kodaira

Ep0100 21, Kofu

EP0100 7, Kōshi

EP0100 9, Nagakute

EP0100 5, Niigata

Ep0100 14, Okayama

Ep0100 13, Osaka

Ep0100 12, Ōbu

Ep0100 11, Ōmura

Ep0100 18, Saitama

EP0100 4, Sapporo

Ep0100 10, Sendai

Ep0100 19, Sendai

Ep0100 16, Shinjuku-ku

Ep0100 17, Shinjuku-ku

EP0100 1, Shizuoka

Ep0100 22, Toyoake

All Listed Sponsors

lead

UCB Japan Co. Ltd.

INDUSTRY

NCT03340064 - A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age | Biotech Hunter | Biotech Hunter